- Trials with a EudraCT protocol (100)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
100 result(s) found for: Play therapy.
Displaying page 1 of 5.
EudraCT Number: 2013-005534-38 | Sponsor Protocol Number: E7080-G000-207 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:Eisai Ltd. | |||||||||||||
Full Title: Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma | |||||||||||||
Medical condition: Refractory or relapsed solid malignancies | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) FR (Ongoing) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004021-26 | Sponsor Protocol Number: RRK 2768 | Start Date*: 2005-10-06 |
Sponsor Name:University Hospital Birmingham | ||
Full Title: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic reg... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-007974-45 | Sponsor Protocol Number: EKZ-AMC001 | Start Date*: 2009-07-16 |
Sponsor Name:AMC | ||
Full Title: Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastoma | ||
Medical condition: relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 years | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000784-16 | Sponsor Protocol Number: NCPACI | Start Date*: 2016-04-15 |
Sponsor Name:Akershus University Hospital | ||
Full Title: Focal cartilage defects in the knee – A randomized controlled trial comparing Autologous Chondrocyte Implantation with arthroscopic debridement | ||
Medical condition: Symptomatic focal cartilage defects in the knee | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002713-34 | Sponsor Protocol Number: ITCC-098 | Start Date*: 2021-12-30 |
Sponsor Name:Princess Maxima Center for Pediatric Oncology in The Netherlands | ||
Full Title: A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors | ||
Medical condition: relapsed/refractory ALK rearranged** or ALK mutated tumors, including relapsed/refractory ALK+ALCL and ALK+IMT. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) NO (Prematurely Ended) BE (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016463-10 | Sponsor Protocol Number: AROT-2009 | Start Date*: 2010-03-18 | |||||||||||
Sponsor Name:LWL University Hospital Bochum | |||||||||||||
Full Title: Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial | |||||||||||||
Medical condition: Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002175-40 | Sponsor Protocol Number: no number | Start Date*: 2008-12-17 |
Sponsor Name: | ||
Full Title: Effect of Botulinum Toxin A Injections and Specific Intensive Rehabilitation Therapy in Children with Hemiparetic Cerebral Palsy on Upper Limb Functions and Skills | ||
Medical condition: Study design: a factorial design with four study groups in which btA alone, intensive rehabilitation therapy aimed at improving bimanual skills alone, a combination of these two and continuing the ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002481-13 | Sponsor Protocol Number: AG881-C-004 | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation | |||||||||||||
Medical condition: Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002932-64 | Sponsor Protocol Number: APHP200133 | Start Date*: 2021-07-23 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP) | |||||||||||||
Full Title: Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD1 inhibitors | |||||||||||||
Medical condition: melonoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000729-55 | Sponsor Protocol Number: 8669-056 | Start Date*: 2011-12-15 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase I Study of Ridaforolimus in Paediatric Patients with Advanced Solid Tumours | |||||||||||||
Medical condition: advanced solid tumours including lymphoma and tumours of the central nervous system | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004967-65 | Sponsor Protocol Number: SP004 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with localized high-risk prostate cancer after primary radiothe... | |||||||||||||
Medical condition: localized high-risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001512-65 | Sponsor Protocol Number: MEMMATCZ | Start Date*: 2012-06-19 |
Sponsor Name:Masaryk University | ||
Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma | ||
Medical condition: recurrent or progressive medulloblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021792-81 | Sponsor Protocol Number: 2010-12 | Start Date*: Information not available in EudraCT |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: SFCE-Metro 01 : Etude de phase II de chimiothérapie métronomique associant celecoxib-methotrexate-vinblastine-cyclophosphamide chez les enfants porteurs d’une tumeur solide en rechute ou en progre... | ||
Medical condition: children and adolescents with relapsed or progressing solid tumours. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003970-89 | Sponsor Protocol Number: CICL670ADE02 | Start Date*: 2007-12-21 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplan... | |||||||||||||
Medical condition: allogeneic hematopoietic cell transplantation with iron overload | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005219-36 | Sponsor Protocol Number: B9E-MC-S378 | Start Date*: 2006-03-06 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | ||
Medical condition: Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001846-15 | Sponsor Protocol Number: CSUC-01/06 | Start Date*: 2006-12-06 |
Sponsor Name:InDex Pharmaceuticals AB | ||
Full Title: A placebo-controlled, randomised, double-blind, single dose proof of concept study of Kappaproct, in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree | ||
Medical condition: Active ulcerative colitis in steroid refractory or steroid dependent patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004441-82 | Sponsor Protocol Number: CA209-908 | Start Date*: 2017-06-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies | |||||||||||||
Medical condition: Primary central nervous system (CNS) malignancies. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) NO (Completed) NL (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023691-33 | Sponsor Protocol Number: MUV-MEMMAT-01 | Start Date*: 2011-05-05 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde | ||
Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT | ||
Medical condition: Recurrent/progressive medulloblastoma, ependymoma and ATRT | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
